...
首页> 外文期刊>Infection and immunity >Mannan as an antigen in cell-mediated immunity (CMI) assays and as a modulator of mannan-specific CMI.
【24h】

Mannan as an antigen in cell-mediated immunity (CMI) assays and as a modulator of mannan-specific CMI.

机译:甘露聚糖在细胞介导的免疫(CMI)分析中作为抗原,并作为甘露聚糖特异性CMI的调节剂。

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Mannan (MAN) extracted from Candida albicans 20A was investigated for its potential as an antigen in the detection of cell-mediated immunity (CMI) in vivo and in vitro and for its ability to modulate CMI when administered intravenously (i.v.). CBA/J mice were either immunized as adults by the cutaneous inoculation of 10(6) viable blastoconidia or colonized as infants (primed) and then boosted cutaneously as adults. When immunized animals were footpad tested with MAN, highly significant delayed-type hypersensitivity (DH) responses were detected. The DH responses to MAN were of a greater magnitude than those noted with the same quantity of cell wall glycoprotein (GP), an ethylenediamine extract of the cell wall which contains both glucan and MAN. In contrast, GP was a better antigen for the detection of CMI responses in an in vitro lymphoproliferative assay with either spleen or lymph node cell suspensions. Mice treated with MAN i.v. prior to the initiation of immunization or between priming and secondary inoculations developed significantly suppressed DH reactions when tested with either MAN or GP. The lowest effective dose of MAN was 250 micrograms, maximum suppression occurred with 500 micrograms, and either dose given 1 week prior to immunization was suppressive. The suppression by MAN was specific for MAN or the MAN-containing GP. Responses to another unrelated candidal antigen, a membrane extract designated BEX, were relatively unaffected. MAN, therefore, was an effective antigen for the detection of CMI in vivo, and its administration i.v. created what appeared to be a MAN-specific suppression since it could be detected with both MAN and a MAN-containing extract from the cell wall. Caution must be exercised in the interpretation of these data, however, since the protein component of each of these extracts has not been characterized with respect to its potential role in the phenomena observed.
机译:研究了从白色念珠菌20A中提取的甘露聚糖(MAN)在体内和体外检测细胞介导的免疫(CMI)方面作为抗原的潜力以及在静脉内(i.v.)施用时调节CMI的能力。 CBA / J小鼠可以通过皮肤接种10(6)种可行的酒裂葡萄球菌成年后进行免疫接种,也可以作为婴儿(初次接种)定居,然后通过皮肤成年后接种。当免疫的动物用MAN进行脚垫测试时,检测到高度显着的迟发型超敏反应(DH)。 DH对MAN的反应比同等数量的细胞壁糖蛋白(GP)(含有葡聚糖和MAN的细胞壁乙二胺提取物)所引起的DH反应强度更大。相反,在脾或淋巴结细胞悬液的体外淋巴增生测定中,GP是检测CMI反应的较好抗原。经MAN i.v.治疗的小鼠在开始免疫之前或在初次接种与二次接种之间,用MAN或GP测试时,DH反应显着抑制。 MAN的最低有效剂量为250微克,最大抑制量为500微克,并且在免疫前1周给予的任何一种剂量都是抑制性的。 MAN的抑制特定于MAN或包含MAN的GP。对另一种无关的候选抗原(一种称为BEX的膜提取物)的反应相对不受影响。因此,MAN是在体内检测CMI及其静脉内给药的有效抗原。产生了似乎是MAN特异的抑制作用,因为可以用MAN和细胞壁中含有MAN的提取物检测到它。但是,在解释这些数据时必须谨慎,因为尚未对这些提取物中每种蛋白质的蛋白质成分在观察到的现象中的潜在作用进行表征。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号